1.Inappropriate use of proton pump inhibitors in a local setting.
Christopher Tze Wei CHIA ; Wan Peng LIM ; Charles Kien Fong VU
Singapore medical journal 2014;55(7):363-366
INTRODUCTIONThere are growing concerns that the use of proton pump inhibitors (PPIs) may be inappropriate in instances that do not conform to evidence-based indications. This point-prevalence study aimed to investigate the frequency, indications and appropriateness of use of PPIs in hospitalised patients on a randomly chosen day.
METHODSOn a randomly chosen day, all inpatients were documented, and those on any form of PPIs on that day were determined. Indications for maintaining these patients on PPIs were obtained from the electronic medical records, which were then recorded and cross-referenced against a list of accepted indications adapted from the US Food and Drug Administration (FDA)-approved list.
RESULTSIn all, 1,025 inpatients were documented. Of the 477 (46.5%) inpatients using PPIs, only 219 (45.9%) fulfilled the FDA-approved indications, while the majority (n = 258, 54.1%) did not. Overall, PPIs were not strictly indicated for use in 206 (43.2%) inpatients, according to FDA criteria. Of the 477 inpatients on PPIs, 52 (10.9%) had borderline indications based on expert consensus/guidelines other than FDA criteria.
CONCLUSIONAlthough the use of PPIs is prevalent in hospitals, less than half of the hospitalised patients using PPIs in our study had evidence-based indications that supported such use. The overuse of PPIs has a negative impact on healthcare costs and may lead to adverse effects. Steps to curb the inappropriate use of PPIs should address factors such as indications for the initiation of PPIs, and reassessment of the need for ongoing PPI use in inpatients upon discharge and during outpatient reviews.
Anemia ; drug therapy ; Dyspepsia ; drug therapy ; Electronic Health Records ; Hospitalization ; Humans ; Inappropriate Prescribing ; statistics & numerical data ; Platelet Aggregation Inhibitors ; therapeutic use ; Practice Guidelines as Topic ; Prevalence ; Proton Pump Inhibitors ; therapeutic use ; Retrospective Studies ; Singapore ; Stomach Diseases ; drug therapy ; United States ; United States Food and Drug Administration
3.Chapter of Gastroenterologists professional guidance on risk mitigation for gastrointestinal endoscopy during COVID-19 pandemic in Singapore.
Tiing Leong ANG ; James Weiquan LI ; Charles Kien Fong VU ; Gim Hin HO ; Jason Pik Eu CHANG ; Chern Hao CHONG ; Tju Siang CHUA ; David Eng Hui ONG ; Benjamin Cherng Hann YIP ; Kok Ann GWEE
Singapore medical journal 2020;61(7):345-349
In this paper, we aimed to provide professional guidance to practising gastrointestinal (GI) endoscopists for the safe conduct of GI endoscopy procedures during the current coronavirus disease 2019 (COVID-19) pandemic and future outbreaks of similar severe respiratory tract infections in Singapore. It draws on the lessons learnt during the severe acute respiratory syndrome (SARS) epidemic and available published data concerning the COVID-19 pandemic. It addresses measures before, during and after endoscopy that must be considered for both non-infected and infected patients, and provides recommendations for practical implementation.
Betacoronavirus
;
Coronavirus Infections
;
epidemiology
;
transmission
;
Disease Transmission, Infectious
;
prevention & control
;
Endoscopy, Gastrointestinal
;
standards
;
Gastroenterologists
;
standards
;
Humans
;
Incidence
;
Pandemics
;
Pneumonia, Viral
;
epidemiology
;
transmission
;
Practice Guidelines as Topic
;
Risk Factors
;
Singapore
;
epidemiology
4.Clinical guidance on endoscopic management of colonic polyps in Singapore.
Tiing Leong ANG ; Jit Fong LIM ; Tju Siang CHUA ; Kok Yang TAN ; James Weiquan LI ; Chern Hao CHONG ; Kok Ann GWEE ; Vikneswaran S/O NAMASIVAYAM ; Charles Kien Fong VU ; Christopher Jen Lock KHOR ; Lai Mun WANG ; Khay Guan YEOH
Singapore medical journal 2022;63(4):173-186
Colonoscopy with endoscopic resection of detected colonic adenomas interrupts the adenoma-carcinoma sequence and reduces the incidence of colorectal cancer and cancer-related mortality. In the past decade, there have been significant developments in instruments and techniques for endoscopic polypectomy. Guidelines have been formulated by various professional bodies in Europe, Japan and the United States, but some of the recommendations differ between the various bodies. An expert professional workgroup under the auspices of the Academy of Medicine, Singapore, was set up to provide guidance on the endoscopic management of colonic polyps in Singapore. A total of 23 recommendations addressed the following issues: accurate description and diagnostic evaluation of detected polyps; techniques to reduce the risk of post-polypectomy bleeding and delayed perforation; the role of specific endoscopic resection techniques; the histopathological criteria for defining endoscopic cure; and the role of surveillance colonoscopy following curative resection.
Adenoma/surgery*
;
Colonic Neoplasms/surgery*
;
Colonic Polyps/surgery*
;
Colonoscopy/methods*
;
Colorectal Neoplasms/pathology*
;
Humans
;
Singapore
;
United States
5.Chapter of Gastroenterologists professional guidance for management of patients with liver disease in Singapore during the COVID-19 pandemic.
Jason Pik Eu CHANG ; Yu Jun WONG ; Wei Lyn YANG ; Kieron Boon Leng LIM ; Poh Seng TAN ; Gim Hin HO ; Benjamin Cherng Hann YIP ; James Weiquan LI ; Chern Hao CHONG ; David Eng Hui ONG ; Tju Siang CHUA ; Charles Kien Fong VU ; Kok Ann GWEE ; Tiing Leong ANG ; Chee Kiat TAN
Singapore medical journal 2020;61(12):619-623
In this paper, we aim to provide professional guidance to clinicians who are managing patients with chronic liver disease during the current coronavirus disease 2019 (COVID-19) pandemic in Singapore. We reviewed and summarised the available relevant published data on liver disease in COVID-19 and the advisory statements that were issued by major professional bodies, such as the American Association for the Study of Liver Diseases and European Association for the Study of the Liver, contextualising the recommendations to our local situation.
COVID-19/epidemiology*
;
Carcinoma, Hepatocellular/therapy*
;
Chronic Disease
;
Hepatitis B, Chronic/therapy*
;
Hepatitis C, Chronic/therapy*
;
Humans
;
Liver Cirrhosis/therapy*
;
Liver Diseases/therapy*
;
Liver Neoplasms/therapy*
;
Liver Transplantation
;
Singapore/epidemiology*